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Abstract L-asparaginase (L-ASP) is a therapeutic
enzyme used clinically for the treatment of childhood acute
lymphoblastic leukemia. L-ASP’s anticancer activity is
believed to be associated primarily with depletion of
asparagine, but secondary glutaminase activity has also
been implicated in its anticancer mechanism of action. To
investigate the effects of L-ASP on amino acid metabolism,
we have developed an LC–MS/MS metabolomics platform
for high-throughput quantitation of 29 metabolites,
including all 20 proteinogenic amino acids, 6 metabolically
related amino acid derivatives (ornithine, citrulline, sar-
cosine, taurine, hypotaurine, and cystine), and 3 poly-
amines (putrescince, spermidine, and spermine) in adherent
cultured cells. When we examined the response of OV-
CAR-8 ovarian cancer cells in culture to L-ASP, aspara-
gine was depleted from the medium within seconds.
Interestingly, intracellular asparagine was also depleted
rapidly, and the mechanism was suggested to involve rapid
export of intracellular asparagine followed by rapid con-
version to aspartic acid by L-ASP. We also found that
L-ASP-induced cell death was more closely associated
with glutamine concentration than with asparagine con-
centration. Time-course analysis revealed the dynamics of
amino acid metabolism after feeding cells with fresh
medium. Overall, this study provides new insight into
L-ASP’s mechanism of action, and the optimized analytical
method can be extended, with only slight modification, to
other metabolically active amino acids, related compounds,
and a range of cultured cell types.
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1 Introduction
L-asparaginase (L-ASP) is a key therapeutic agent for the
treatment of childhood acute lymphoblastic leukemia
(ALL). L-ASP catalyzes the deamidation of asparagine and
glutamine into aspartic acid and glutamic acid, respec-
tively, releasing ammonia in the process. The resulting
amino acid (AA) deprivation induces cell death in tumor
cells that lack the ability to synthesize sufficient levels of
those AAs (Balasubramanian et al. 2013). Expression of
asparagine synthetase (ASNS), which catalyzes the syn-
thesis of asparagine, is negatively correlated with L-ASP’s
anticancer activity in leukemia cell lines (Fine et al. 2005;
Hutson et al. 1997; Scherf et al. 2000; Su et al. 2008),
leukemia patient samples (Leslie et al. 2006), and ovarian
cancer cell lines (La Spina et al. 2010; Lorenzi et al. 2006,
2008; Lorenzi and Weinstein 2009). However, asparagine
deamidation alone may be insufficient to induce cell death
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(Asselin et al. 1989; Kitoh et al. 1992), prompting the
search for additional metabolites that mediate the cellular
response to L-ASP treatment.
In previous studies, we and others have reported a rationale
for extending L-ASP treatment to some types of solid tumors
(Bussey et al. 2006; Lorenzi et al. 2006, 2008; Scherf et al.
2000; Yu et al. 2012). To further substantiate that rationale, we
initiated metabolomics investigations to probe L-ASP’s
mechanism of action. Accordingly, we examined the effects
of L-ASP on AA metabolism since L-ASP is known to
degrade asparagine and glutamine enzymatically. To optimize
sample preparation for analysis of AAs in mammalian cells,
we examined various conditions for quenching cellular
metabolism, extracting metabolites, removing proteins, and
normalizing data. We also developed and optimized an LC–
MS/MS method to satisfy the following criteria: label-free
(i.e., no pre- or post-column derivatization), sufficient chro-
matographic retention to separate polar AAs, resolution of
isotopic and isobaric AAs, short run time, high sensitivity, and
large linear dynamic range. We used the optimized protocol to
analyze AA metabolism in response to L-ASP treatment in
cultured ovarian cancer cells. The protocol can be extended to
other mammalian cell types to study the metabolism of AAs
and similar compounds.
2 Materials and methods
During the course of method development, we analyzed a
variety of process parameters, calibration standards, and
data normalization strategies. The following materials and
methods are based primarily on the optimal set of condi-
tions defined by that process.
2.1 Chemicals and reagents
Standards for cysteine, asparagine, glutamine, tryptophan,
ornithine, citrulline, putrescine, spermine, spermidine, sar-
cosine, taurine, hypotaurine, a mixture containing 17 AAs, an








15N2-tryptophan were all purchased from
Sigma Aldrich (St. Louis, MO). d8-putrescine was purchased
from CDN isotopes (Quebec, Canada). Pronase and car-
boxypeptidase Y were purchased from Calbiochem (Darms-
tadt, Germany). LC/MS-grade water, methanol, and
acetonitrile (ACN) were purchased from Burdick and Jackson
(Muskegon, MI). Formic acid and heptafluorobutyric acid
(HFBA) were obtained from Sigma Aldrich. L-asparaginase
was obtained from Lundbeck pharmaceuticals (Deerfield, IL).
Medium for cell culture (RPMI 1640) and fetal bovine sera
(FBS) were purchased from Thermo HyClone (Logan, Utah).
The liquid chromatography column (Zorbax SB C-18;
3.0 9 100 mm, 1.8 lm particle size) was obtained from
Agilent (Santa Clara, CA). All other chemicals were of ana-
lytical grade and obtained from Sigma.
2.2 Cell culture
OVCAR-8 cells were routinely maintained in RPMI 1640
containing 5 % FBS and 1 % (2 mM) L-glutamine (Hy-
Clone). Cultures were grown in an atmosphere of 5 % CO2
at 37 C. For experiments, 120,000 cells were seeded in
10 cm polypropylene dishes for 48 h, then treated with
fresh medium containing vehicle, 0.1 U/mL L-ASP (EC10),
or 0.5 U/mL L-ASP (EC50) for 0, 0.01, 8, 24, or 48 h. At
the time of treatment (48 h) and time of harvesting the final
time point (96 h total), cells were approximately 40 and
80 % confluent, respectively. Zero-time points reflect the
untreated state, whereas 0.01 h time points reflect samples
that were exposed to the indicated treatment for approxi-
mately 30 s and immediately processed as described
below. Parallel dishes containing medium without cells
were subjected to similar treatments to distinguish between
efflux from the cells and degradation processes that occur
in the medium. OVCAR-4 cells were also cultured and
treated with 0.5 U/mL L-ASP and processed as above.
2.3 Sample preparation
2.3.1 General protocol
At indicated time points, cells were subjected to washing
and extraction of AAs by quenching, addition of extraction
solvent, scraping, and disruption of cells for *30 s using a
Disruptor Genie (Scientific Industries Inc.). Samples were
then centrifuged at 20,000g for 4 min, and supernatants
were collected. Cell pellets were saved for DNA analysis
for data normalization (Silva et al. 2013). Protein was
precipitated and removed by transferring 200 lL of sample
to 600 lL of dry ice-cooled 100 % methanol containing
internal standards. Precipitated lysates were collected and
evaporated to dryness using a SpeedVac (Thermo Scien-
tific). Dried cell lysates were reconstituted in 100 lL
mobile phase A. Corresponding samples of medium were
processed by combining 200 lL of sample with 600 lL of
dry ice-cooled methanol containing internal standards,
evaporating to dryness, and reconstituting in 200 lL
mobile phase A. Accordingly, final concentrations of cell
and medium samples were 2:1 and 1:10, respectively, of
the original concentrations.
2.3.2 Optimization of quenching
To capture an accurate snapshot of intracellular AA con-
centrations, it is important to quench metabolism and other
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cellular processes that could introduce artifacts during the
sample preparation process. Building on previous quench-
ing optimization efforts of others (Danielsson et al. 2010;
Meinert et al. 2013; Sellick et al. 2011), we compared the
quenching abilities of 60 % MeOH containing ammonium
bicarbonate (0.85 % w/v) (MeOH/AMBIC), 60 % MeOH
containing 70 mM HEPES, and 0.9 % NaCl. Quenching
buffer was added directly onto the adherent cells and
removed immediately after rinsing the cells twice.
2.3.3 Optimization of extraction
AA concentrations measured in cells were compared for
extractions performed with multiple combinations of organic
solvents, methanol:acetonitrile = 1:1, methanol:chloro-
form:water = 7:2:1, and acetonitrile:water = 1:1.
2.4 Liquid chromatography and mass spectrometry
Liquid chromatography was performed on an Agilent 1290
Infinity UHPLC system equipped with a Zorbax SB C-18
column (3.0 9 100 mm, 1.8 lm particle size) at 25 C
column temperature. The mobile phase consisted of
(A) water and (B) acetonitrile, each containing 0.3 %
HFBA and 0.5 % formic acid. Gradient conditions were:
0.01 to 2 min = 2 to 30 % B; 2 to 4.1 min = 30 to 40.0 %
B; 4.1 to 4.8 min = 40 to 45 % B; 4.8 to 4.9 min = 45 to
90 % B; 4.9 to 5.5 min = 90 % B; 5.5 to 5.6 min = 90 to
2 % B; and 5.6 to 8.0 min = 2 % B. Injection volume was
5.0 lL and flow rate was 0.3 mL/min. MS/MS analysis
was performed on an Agilent 6460 triple quadrupole
equipped with a jet stream electrospray ionization (ESI)
source. Multiple reaction monitoring (MRM) was per-
formed in the positive ion mode. Other MS parameters
included: gas temperature at 300 C, drying gas at 7 L/min,
nebulizer pressure at 50 psi, sheath gas temperature at
325 C, sheath gas flow at 10 L/min, capillary voltage at
3750 V, and nozzle voltage at 0 V. Source conditions were
optimized for each AA by the Mass Hunter Optimizer
B.04.01. The MRM transitions and optimized parameters
(e.g., collision energy, fragmentor voltage, and dwell time)
used for each AA are summarized in Supplementary
Table 1.
2.4.1 Standards and internal standards
A mixture of 17 AA standards was used for initial assay
development. Standards for cysteine, asparagine, gluta-
mine, tryptophan, ornithine, citrulline, putrescine, sperm-
ine, spermidine, sarcosine, taurine, and hypotaurine were
combined with the mixture of 17 AAs for construction of
calibration curves and optimization of MS parameters.
Calibration standard mixes were prepared in mobile phase
A at concentrations ranging from 1 nM to 5 mM. An
internal standard mixture was made by combining an algal








Optimal concentrations of internal standards were found to
be 100 lg/mL of algal mix and 10 lM each of labeled
asparagine, glutamine, cysteine, tryptophan, and putres-
cine. The individual AA concentrations in the algal mix are
reported in Supplementary Table 3. Optimal fragmentor
voltage, collision energy, and MRM transitions were
determined for labeled and unlabeled AAs (Supplementary
Tables 1 and 2).
2.4.2 LC/MS/MS data acquisition and analysis
Mass Hunter (version B.04.01) was used for data acquisi-
tion. Mass Hunter Qualitative Analysis and Quantitative
Analysis were used for data processing. The most abundant
MRM transition was selected for each analyte (Supple-
mentary Table 1). The area under the curve for each ana-
lyte of interest and its corresponding isotopic internal
standard was obtained from the analyte’s MRM transition
and retention time. The ratio of those areas was further
normalized by DNA concentration (a surrogate for cell
number).
2.4.3 Method validation
Calibration standards were analyzed in triplicate for each
unlabeled compound to determine retention times, limits of
detection (LOD), limits of quantitation (LOQ), coefficient
of regression (R2), and dynamic range. Calibration curves
created for each analyte were fitted using linear regression.
To address assay reproducibility, calibration standards
were analyzed in triplicate on three different days. The
coefficient of variation (%CV) was calculated at each
concentration within the linear range of the assay.
3 Results and discussion
3.1 Sample preparation
3.1.1 Optimization of quenching
Sufficiently rapid quenching of metabolism is a major
requirement for the measurement of metabolites in cells or
tissues because the half-lives of some metabolically active
compounds can be just a few seconds (Dietmair et al. 2010;
Kronthaler et al. 2012; Sellick et al. 2009; Tran et al. 2012)
The ideal quenching solution should stop metabolism
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immediately and also reduce leakage of intracellular
metabolites (Kronthaler et al. 2012). For that purpose, rapid
quenching with cold organic solvents has been used pre-
viously (De Jonge et al. 2012; Kronthaler et al. 2012;
Lorenz et al. 2011; Sellick et al. 2009; Tran et al. 2012).
Quenching with ice-cooled 0.9 % NaCl or dry ice-cooled
methanol (60 %) containing 0.85 % ammonium bicarbon-
ate (MeOH/AMBIC) has been reported to be effective
(Kronthaler et al. 2012; Sellick et al. 2009; Tran et al.
2012). On the basis of those previous reports, we compared
quenching by dry ice-cooled MeOH/AMBIC and ice-
cooled 0.9 % NaCl. The efficiency of quenching was
assessed on the basis of intracellular AA concentrations,
which reflect both metabolic and transport processes.
Quenching cells with MeOH/AMBIC resulted in 1.7- to
10-fold greater intracellular AA concentrations than did
quenching with 0.9 % NaCl (Fig. 1a). Therefore, cells
were washed with MeOH/AMBIC to quench metabolism.
Substitution of 70 mM HEPES for AMBIC yielded no
significant increase in intracellular signal intensity (data
not shown).
3.1.2 Optimization of extraction
The next sample preparation step to be optimized was
extraction of AAs from cells. We compared three different
combinations of quenching and extraction: quenching with
MeOH/AMBIC followed by extraction with MeOH/ACN
(1:1) (Dietmair et al. 2010); quenching with MeOH con-
taining 70 mM HEPES followed by extraction with
MeOH/ACN (1:1) (Kronthaler et al. 2012), and quenching
with MeOH/AMBIC followed by extraction with MeOH/
chloroform/water (7:2:1) (Bi et al. 2013). Although we saw
no significant differences among the quenching/extraction
combinations evaluated, we selected MeOH/AMBIC
quenching followed by MeOH/chloroform/water (7:2:1)
extraction because it yielded the greatest signal intensity
for the metabolically important AA glutamine (Fig. 1b).
Sample preparation was further optimized by comparing
cell disruption and protein precipitation conditions. When
we compared no cell disruption with cell disruption for
30 s, cell disruption yielded 1.5- to 2.0-fold greater signal
intensity across the 29 analytes (data not shown). Next, we
compared protein precipitation using just 100 % methanol
or acetonitrile (without a filter plate) with protein precipi-
tation using 10 different protein precipitation/filtration
plates. The signal intensity for most metabolites was
greatest when we used the Phenomenex Strata plate (Phe-
nomenex, Torrance, CA) (data not shown). The filtrates
were evaporated to dryness at room temperature using a
SpeedVac, stored as dry samples at -80 C, and recon-
stituted with mobile phase A at the time of analysis. Final
concentrations of the cell and medium samples were 2:1
and 1:10, respectively, of the original concentrations.
3.2 LC–MS/MS method development and validation
Our first goal was to develop a reverse-phase chromatog-
raphy method capable of retaining polar AAs beyond the
void volume without the need for pre- or post-column
derivatization. That was achieved using ion-pairing with
heptafluorobutyric acid (HFBA) (Fig. 2). Notably, HFBA
reduced ion suppression for most of the polar AAs (data
not shown) and also increased the chromatographic sepa-
ration between isomeric compound pairs (e.g., leucine/
isoleucine) and between isobaric compound pairs (e.g.,
glutamine/lysine) (Supplementary Figure 1). Figure 2
illustrates the final chromatographic separation achieved
for the 29 metabolites. Optimal MRM transitions, frag-
mentor voltage, collision energy, and cell accelerator
voltage were identified for each unlabeled and isotopically


















































































 Cell quench with 0.9% NaCl





























































































 MeOH/AMBIC with MeOH:ACN (1:1)
 Ammonium Formate with MeOH:ACN (1:1)
 MeOH/AMBIC with MeOH:TCM:Water (7:2:1)
A
Fig. 1 Optimization of sample preparation protocol. a Comparison of
metabolism quenching by dry ice-cooled (-40 C) MeOH/AMBIC
and ice-cooled 0.9 % NaCl. Quenching buffer was added directly
onto OVCAR-8 cells and removed immediately after rinsing the cells
twice. b Comparison of solvent combinations for metabolite quench-
ing and extraction: MeOH/AMBIC with MeOH/ACN (1:1), ammo-
nium formate with MeOH/ACN (1:1) versus MeOH/AMBIC with
MeOH/chloroform/water (7:2:1). Error bars represent standard error
of the mean for three biological replicates, one-way ANOVA,
*p B 0.05, **p B 0.01
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Tables 1 and 2). To improve assay performance and pre-
vent MS source contamination, the first minute of post-
column eluent was diverted to waste. The method was
validated by analyzing calibration standards in triplicate for
each unlabeled compound to determine linear dynamic
range, R2, retention time, limit of detection (LOD), and
limit of quantitation (LOQ) (Table 1). LODs ranged from
0.002 (for alanine) to 0.250 lM (for asparagine), LOQs
ranged from 0.007 to 0.760 lM, and the linear dynamic
range was two to five log units. Inter- and intra-day
reproducibility of retention time was also excellent with
%CVs ranging from 0 to 0.47 %.
The use of stable isotope-labeled AAs as internal stan-
dards enabled us to correct for drift in instrument perfor-
mance and for variation that arose downstream of sample
precipitation for all individual AAs. All labeled AAs co-
eluted with their non-labeled counterparts. In total, 29
external AA standards and 21 isotope-labeled internal
standards were included in the 8-min assay. Sarcosine was
normalized using 13C2,
15N-glycine as the internal stan-
dard. Polyamines, such as spermine and spermidine, for
which no isotopically labeled analogs were available, were
normalized using d8-putrescine as the internal standard.
Cystine (Cys-Cys dipeptide) was normalized using 13C3,
15N-cysteine as the internal standard. Taurine, hypotaurine,
ornithine, and citrulline were normalized using 13C4,
15N2-
asparagine as the internal standard. In addition to the
comprehensive inclusion of internal standards for accurate
quantitation, specific advantages of the LC–MS/MS
method include: no requirement for derivatization,
improved chromatographic retention of polar AAs,





























































































































































Fig. 2 MRM transitions of all 29 metabolites (200 lM). Liquid
chromatography was performed on an Agilent 1290 Infinity UHPLC
system equipped with a Zorbax SB C-18 column (3.0 9 100 mm,
1.8 lm) at 25 C column temperature. The mobile phases consisted
of water and acetonitrile each containing 0.3 % HFBA and 0.5 %
formic acid














0.992 3.11 0.002 0.007
Arginine 16.0 nM–
750 lM
0.989 4.67 0.006 0.016
Asparagine 0.76 lM–
500 lM
0.998 2.52 0.250 0.760
Aspartic acid 0.45 lM–
375 lM
0.998 3.09 0.150 0.450
Citrulline 7.0 nM–
250 lM
0.989 3.55 0.002 0.007
Cysteine 0.23 lM–
250 lM
0.981 3.66 0.076 0.230
Cystine 66.0 nM–
312.5 lM
0.999 4.16 0.022 0.066
Glutamic acid 66.0 nM–
750 lM
0.992 3.37 0.022 0.066
Glutamine 49.0 nM–
500 lM
0.996 3.13 0.016 0.049
Glycine 0.14 lM–
375 lM
0.989 2.72 0.049 0.140
Histidine 99.0 nM–
750 lM
0.995 4.47 0.033 0.099
Hypotaurine 0.67 lM–
5,000 lM
0.990 1.81 0.220 0.670
Isoleucine 27.0 nM–
375 lM
0.988 4.74 0.009 0.027
Leucine 70.0 nM–
750 lM
0.983 4.89 0.023 0.070
Lysine 75.0 nM–
375 lM
0.996 4.39 0.025 0.075
Methionine 0.44 lM–
750 lM
0.993 4.44 0.144 0.440
Ornithine 0.18 lM–
500 lM
0.995 4.52 0.059 0.180
Phenylalanine 0.10 lM–
750 lM
0.991 5.16 0.033 0.100
Proline 80.0 nM–
375 lM
0.993 3.79 0.026 0.080
Putrescine 1.42 lM–
250 lM
0.978 4.77 0.470 1.420
Sarcosine 0.10 lM–
250 lM
0.990 3.44 0.033 0.100
Serine 0.20 lM–
750 lM
0.983 2.60 0.070 0.200
Spermidine 4.26 lM–
250 lM
0.983 5.21 1.410 4.260
Spermine 53.0 nM–
250 lM
0.991 5.76 0.017 0.053
Taurine 67.0 nM–
150 lM
0.980 1.51 0.022 0.067
Threonine 22.0 nM–
750 lM
0.996 3.32 0.007 0.022
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resolution of isotopic and isobaric AAs, short run time,
and, on the basis of those improvements, greater mea-
surement accuracy, sensitivity, and linear dynamic range.
While evaluating and validating the LC–MS/MS
method, we observed minor glutamine degradation that
was determined to be due to cyclization to pyroglutamic
acid in the ESI ion source. A separate manuscript (Purwaha
et al. manuscript in preparation) characterizes that reaction.
Of note, we found that using 13C, 15N-glutamine as an
internal standard serves as a basis for data correction,
accounting for in-source conversion of glutamine to pyro-
glutamic acid.
3.3 Amino acid metabolism in ovarian cancer cells
treated with L-ASP
We used our optimized assay to conduct a time course
analysis of AA concentrations in response to L-ASP
treatment of ovarian cancer cells and gained new insight
into the drug’s mechanism(s) of action (Figs. 3, 4, 5, and
Supplementary Fig 2). First, both low (0.1 U/mL) and high
(0.5 U/mL) doses of L-ASP fully depleted asparagine
within seconds in the medium (with or without cells
present) and within 8 h in OVCAR-8 cells (Fig. 3a, b).
Those observations prompted the question: since L-ASP
cannot penetrate cells, what is the mechanism by which
intracellular asparagine is depleted in response to L-ASP?
To address that question, we first tested the hypothesis
that L-ASP causes an increase in the rate of incorporation
of intracellular asparagine into cellular protein. Total pro-
tein was extracted from OVCAR-8 cells treated with or
without L-ASP (0.5 U/mL) and subsequently hydrolyzed
using proteases to yield free amino acids (Sweeney and
Walker 1993). Comparison of the asparagine levels
between the two groups showed no differences between
vehicle- and L-ASP-treated cells (data not shown). Hence,
the mechanism of intracellular asparagine depletion in
response to L-ASP does not appear to involve increased
rate of incorporation into cellular protein.
To further investigate how intracellular asparagine is
depleted in response to L-ASP treatment, we next pre-
treated OVCAR-8 cells with 13C4-labeled asparagine to test
the hypothesis that asparagine is rapidly exported from
cells in response to L-ASP treatment. After 30 min of
incubation with medium in which the usual 12C4-aspara-
gine was replaced with 13C4-asparagine (50 mg/L),
13C4-
asparagine comprised approximately 90 % of the total
intracellular asparagine. The cells were then treated for
*30 s with fresh medium containing 12C4-asparagine and
0.5 U/mL L-ASP. In that short time frame, extracellular
13C4-aspartic acid increased from 0 to about 40 % of the
total aspartic acid content (data not shown) possibly either
by export of 13C4-aspartic from the intracellular compart-
ment or by first exporting 13C4-asparagine followed by
L-ASP-mediated degradation of asparagine to aspartic acid
in the extracellular compartment. Given that L-ASP com-
pletely depleted extracellular asparagine within 30 s
(Fig. 3a), it seems reasonable to speculate that L-ASP
causes a strong, extracellularly-directed asparagine gradi-
ent that leads to asparagine efflux from the intracellular
compartment followed by L-ASP-mediated degradation to
aspartic acid in the extracellular compartment. Hence, the
mechanism by which L-ASP depletes intracellular aspara-
gine appears to involve rapid export of intracellular
asparagine to the outside of the cell, where it is rapidly
converted to aspartic acid by L-ASP.
To assess whether the 0.5 U/mL L-ASP-induced
increase in intracellular aspartic acid concentration was
derived from asparagine, we next pre-treated OVCAR-8
cells with 13C4-asparagine for 30 min followed by vehicle
or L-ASP (0.5 U/mL) treatment. The resulting time course
(with measurements at 0, 0.01, 0.5, and 1 h) indicated that
within 30 s of L-ASP treatment, extracellular 13C4-aspar-
agine was fully converted into 13C4-aspartic acid (Supple-
mentary Figure 3A). Intracellular 13C4-asparagine
decreased from 90 to 44 % of the total (12C ? 13C), and
intracellular 13C4-aspartic acid increased from 50 to 75 %,
suggesting that 25 % of the latter L-ASP-induced increase
in 13C4-aspartic acid was derived from intracellular
asparagine (Supplementary Figure 3B). These findings
suggest that the rapid increase in intracellular aspartic acid
is derived in part from intracellular asparagine, but most of
it may be derived from the rapid uptake of extracellular
aspartic acid.
The observation of rapid asparagine depletion (Fig. 3a, b)
was unexpected primarily because 0.1 and 0.5 U/mL
L-ASP were previously noted to cause approximately 10
and 50 % cell death, respectively, after 48 h (Lorenzi et al.















1.000 5.51 0.130 0.390
Tyrosine 0.47 lM–
750 lM
0.992 4.31 0.150 0.470
Valine 48.0 nM–
750 lM
0.984 4.19 0.016 0.048
External calibration standards were analyzed for each compound to
determine dynamic range, R2, retention time, LOD, and LOQ of
unlabeled compounds
a Lower limit of quantitation
b Higher limit of quantitation
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metabolite depletion and the overall drug response
prompted the question: which other metabolites might be
associated with L-ASP-induced cell death? Interestingly,
depletion of glutamine in both the extracellular compart-
ment (culture medium) and intracellular compartment (cell
pellet) reached a maximum at 24 h, which was sustained
through 48 h (Fig. 3e, f), suggesting that glutamine is
closely associated with cell death in response to L-ASP
treatment in OVCAR-8 cells. Notably, glutamic acid con-
centrations were elevated across the entire time series





























































































 L-Asp 0.1U NC


















 L-Asp 0.1U NC

















 L-Asp 0.1U NC

















 L-Asp 0.1U NC




























































Fig. 3 Time course analysis of the four canonical AAs involved
directly in enzymatic activity of L-ASP. OVCAR-8 cells and medium
(after incubation with cells or no cells (‘‘NC’’)) were collected after
treatment with vehicle, low dose (0.1 U/mL), or high dose (0.5 U/mL) of
L-ASP for 0, 0.01, 8, 24, or 48 h. Concentration of asparagine (a, b),
aspartic acid (c, d), glutamine (e, f), and glutamic acid (g, h) in
medium and cell lysates, respectively. Cell lysate data were
normalized to DNA concentration of the corresponding cell pellet.
Error bars represent standard error of the mean for three biological
replicates, paired t test, *p B 0.05. The spikes in intensity for cells
were reproducible in multiple experiments (see text)
Amino acid response to L-asparaginase 915
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following treatment with an EC50 dose (0.5 U/mL) of
L-ASP, whereas glutamic acid concentrations following an
EC10 dose (0.1 U/mL) were unchanged relative to the
vehicle control. To further probe whether the elevated
glutamic acid concentrations played a role in cell death by
the EC50 dose (0.5 U/mL) of L-ASP, glutamic acid was
tested for anticancer activity toward OVCAR-8 cells but
had no effect on cell proliferation (as measured by CellT-
iter Blue assay; data not shown).
Another unexpected feature of the AA response to
treatment with high dose (0.5 U/mL) L-ASP was an
immediate increase in the intracellular concentrations of all




























































































































































































































































































































































































































Fig. 4 Time course analysis of AAs and derivatives in OVCAR-8 cells
collected after treatment with vehicle, low dose L-ASP (0.1 U/mL), or
high dose L-ASP (0.5 U/mL) for 0, 0.01, 8, 24, or 48 h. Data were
normalized to DNA concentration of the corresponding cell pellet.
Error bars represent standard error of the mean for three biological
replicates, paired t test, *p B 0.05. Two metabolites not represented in
the figure were found to be below the limit of detection
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AAs except asparagine, as shown by the upward spike at
the 0.01 h time point (Figs. 3, 4). That phenomenon has
been repeated in multiple, independent follow-up experi-
ments by multiple investigators in our laboratory (data not
shown). We initially hypothesized that 0.5 U/mL L-ASP
rapidly up-regulates AA concentrations through the
induction of autophagy. However, additional experiments
conducted using wild-type and ATG5 (a vital autophagy
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Fig. 5 Time course analysis of AAs and their derivatives in medium
incubated with OVCAR-8 cells or without cells (‘‘NC’’) in vehicle, in
low dose L-ASP (0.1 U/mL), or in high dose L-ASP (0.5 U/mL)
L-ASP for 0, 0.01, 8, 24, or 48 h. Error bars are standard error of the
mean for three biological replicates, paired t test, *p B 0.05. Six
metabolites not represented in the figure were found to be below the
limit of detection
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regulatory gene)-knockout mouse embryonic fibroblasts
(MEFs) showed that the initial increase of intracellular
amino acid concentration with L-ASP treatment was
observed irrespective of autophagy status, suggesting that
autophagy may not be involved in the rapid metabolite
increase.
Two additional features of the observed AA responses
to fresh medium (vehicle) and L-ASP are worth further
discussion. First, after routine feeding of OVCAR-8 cells
with fresh medium, the intracellular concentrations of
most AAs were depleted within 8 h, and all AAs were
generally depleted by 24 h (Figs. 3, 4). Those trends were
presumably due to metabolic consumption, since AAs are
needed to maintain cancer cell growth and proliferation.
Consistent with those observations, the polyamine
putrescine was converted into spermine (a higher order
polyamine) over 24 h, suggesting anabolic behavior of
polyamines in OVCAR-8 cells.
Second, although the majority of extracellular AA
concentrations remained constant, Fig. 5 illustrates that the
concentrations of several AAs decreased in the medium
over time, suggesting that they were consumed by the
proliferating OVCAR-8 cells, particularly at the 48 h time
point. Only one AA, alanine, was apparently exported into
the medium during that timeframe. The AA threonine
showed a dose-dependent depletion in medium (Fig. 5)
with L-ASP treatment but this phenomena was undetect-
able in the cell lysates. Threonine levels were also lower in
medium incubated with cells in comparison to medium
incubated without cells, suggesting that cells take up and/or
metabolize threonine almost instantaneously.
4 Concluding remarks
We describe here the development and application of a
targeted LC–MS/MS metabolomics platform for high-
throughput quantitation of free AAs and related metabo-
lites to study the mechanism of action of L-ASP. The study
revealed that inhibition of cell metabolism by L-ASP was
more closely associated with glutamine concentration than
asparagine concentration. The platform and optimized
method described here can be extended to include mea-
surement of other metabolically active AAs and related
compounds in adherent cell lines or, with slight modifica-
tion, in suspension cell lines.
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